DR2 The Relationship Between Pseudoephedrine Sales and Clandestine Methamphetamine Labs  by Talbert, J. et al.
cccodex codes. Quality of care measures included accountability measures (HbA1C
tested, foot examination and eye examination), treatmentmeasures (ACEIs/ARBs, st-
atins), health related quality of life measures (HRQoL, physical component scale- PCS
andmental component scale-MCS) and total health care expenditure. The differences
in processes of care were determined using multiple logistic regression models and
differences in the outcomes of care (HRQoL and total health care expenditure) were
examinedusingmultiple linear regressionmodels that includedbaseline socio-demo-
graphic factors, clinical factors and co-medications. RESULTS: Nearly 30% of hyper-
tensive diabetics received HbA1c test, feet examination and an eye examination at
least once a year, 61% received ACEIs/ARBs and 56% received statins. Multiple
logistic regressions found that therewere no differences in the accountabilitymea-
sures and treatment measures among patients with and without dementia. Pa-
tients with dementia had significantly lower scores on HRQoL measures (mean
PCS- 29.4 9.1 vs 37.2 12.2, p 0.001; mean MCS- 41.9 12.2 vs. 48.3 11.3, p
0.001) and more than 80% increase in total health care expenditure than patients
without dementia. CONCLUSIONS: The study found that despite the recommen-
dations by American Diabetes Association, the overall accountability measures
(HbA1C tested, foot examination and eye examination) and treatment measures
(ACEIs/ARBs, statins) were low in the elderly hypertensive diabetic patients. Al-
though the processes of care were similar, there were disparities in HRQoL and
total health care expenditures among patients with andwithout dementia indicat-
ing need of targeted efforts to improve quality of care measures in this complex
population.
CV2
THE HIDDEN BURDEN OF PRESCRIPTION COST CUTTING IN A DIAGNOSED
ATRIAL FIBRILLATION POPULATION IN THE UNITED STATES
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OBJECTIVES: To determine the loss of work productivity and activity impairment
(WPAI) due to non-compliant cost cutting in a diagnosed Atrial Fibrillation (AF)
population. METHODS: The study consisted of data from the 2011 US National
Health and Wellness Survey (NHWS), a web-based survey of 75,000 patients’ de-
mographics, health care attitudes and health outcomes. Non-compliant cost cut-
ting strategies were defined as taking less medication than prescribed, cutting
tablets in half, buying fewer tablets, not filling prescriptions because of costs, not
filling prescriptions and using over-the-counter medications instead, or buying
prescriptions less often. Compliant strategies were defined as asking for generic
alternatives, asking for samples, buying prescriptions multiple months at a time
through mail order, using coupons, and using a discount card. Generalized linear
regression models were used to determine the burden of engaging in non-compli-
ant strategies on WPAI, controlling for demographics, health history, insurance
status, and comorbidities. RESULTS: Out of 1,046 diagnosed AF patients taking a
prescription medication for AF, 19.8% reported using non-compliant cost cutting
strategies, 41.3% reported using compliant strategies only, and 38.9% reported not
using any cost cutting strategies. After controlling for demographics, health his-
tory, and comorbid conditions, among the employed respondents, non-compliant
patients reported greater presenteeism (28.4%) and overall work productivity loss
(29.9%) comparedwith patientswho practice only compliant cost cutting strategies
(11.8% vs. 12.8%, respectively, p0.03 for both) . Non-compliant patients reported
significantly more activity impairment (45.4% vs. 37.5%, p0.003) before adjust-
ments, but after adjustments, no differences were found. CONCLUSIONS: In AF
patients, participating in non-compliant cost cutting strategies was found to be
associated with greater presenteeism and overall work productivity loss. These
patients should be identified and guided to improve compliance to their prescrip-
tion medications to help avoid impairment while working.
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OBJECTIVES: To determine if there were differences between statins in terms of car-
diovascular event rate and total cost among those who initiate therapy in a large
managed carepopulation.METHODS: Pharmacy andmedical claims datawere used
from 14 geographically diverse health plans in the US covering approximately 14
million members. Members had at least one pharmacy claim for atorvastatin, ro-
suvastatin, simvastatin, simvastatin/ezetimibe, pravastatin, or lovastatin during
the period between January 1, 2007 and December 31, 2008. Members who initiated
therapywere followed for 36months. Patientswere stratified into either primary or
secondary prevention. Outcomes included cardiovascular event rate and total ad-
justed cost. Multiple regression models were used to examine the association be-
tween statin therapy and cardiovascular event rate or healthcare cost while con-
trolling for demographics and observable clinical characteristics. RESULTS: A total
of 31,224 members were included, of which 25,055 and 6,169 were identified as pri-
mary and secondary prevention, respectively. Adjusted odds ratios for cardiovascular
event rates were not significantly different among the statins in either cohort. In the
primary prevention cohort, total adjusted cost was lowest for simvastatin ($13,166),
followed by lovastatin ($13,394), pravastatin ($13,811), atorvastatin ($18,209), rosuvas-
tatin ($19,194), and simvastatin/ezetimibe ($19,254); overall p0.0001. In the second-
ary prevention cohort, total adjusted cost was lowest for simvastatin ($25,111) fol-
lowed by lovastatin ($27,246), pravastatin ($27,282), simvastatin/ezetimibe ($30,412),
atorvastatin ($30,872), and rosuvastatin ($33,295); overall p0.0001. In the primary
preventioncohort, adjustedpharmacycostwas lowest for lovastatin ($4,417), followed
by simvastatin ($4,420), pravastatin ($4,715), atorvastatin ($8,210), simvastatin/
ezetimibe ($9,204), and rosuvastatin ($9,276); overall p0.0001. Similar pharmacy cost
patterns were observed in the secondary prevention cohort. CONCLUSIONS: There
appears to be similar rates of cardiovascular events among the statins. Branded
statins were generally associated with higher total cost compared to generic st-
atins, likely driven by differences in pharmacy cost.
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OBJECTIVES: The first objective of this study was to compare the predictive ability
of theGRACERisk Prediction Index (GRPI) and theCharlsonComorbidity Index (CCI)
in determining in-patient mortality, mortality within six months of discharge, and
occurrence of a second coronary event or procedure after discharge, in patients
who were admitted to a university hospital for the treatment of acute coronary
syndrome (ACS). The second objective was to determine if combining GRPI and CCI
in prediction models improved the ability to determine the same outcomes.
METHODS: Data used for this study were obtained from a large academic health
system’s acute coronary syndrome patient registry. Registry data is abstracted
from the medical record as well as from patient self-report by a telephone fol-
low-up survey 6 to 12 months after discharge. Logistic regression/ROC was used to
derive c-statistics for CCI, GRPI, and CCI-GRPI combined predictivemodels for each
of outcomes. Likelihood ratio tests were conducted to determine the contribution
of CCI when added to predictive models using the GRPI. RESULTS: A total of 1202
patients had complete data from the index hospitalization. The GRPI model had a
higher c-statistic (0.73) versus CCI model (0.68) and similar to the combined model
(0.75) to predict in-patient death; the c-statistics formodels predicting death during
the follow-up period were similar (GRPI0.74, CCI0.77, Combined0.81); and all
were similar in predicting secondary events after discharge (GRPI0.57, CCI0.60,
Combined0.58). The Likelihood ratio analysis demonstrated that adding the CCI
to existing predictive GRPI models was beneficial primarily for predicting second-
ary events post discharge. CONCLUSIONS: The CCI modestly improves models
using GRPI to predict death after discharge for an ACS event. It is an acceptable
alternative to the GRPI in predicting death and secondary events if data to derive
the GRPI are not available.
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OBJECTIVES: While considerable progress has been made, the overall global bur-
den of disease continues to escalate. The promise of translational medicine as-
sumes matching basic science to greatest unmet need can reduce the burden of
disease. Few studies have investigated the relationship between drug development
and public health priorities; fewer still have correlated funding, development and
global burden as a systemic response to unmet need. To fill crucial evidence gaps,
we investigated the relationship between the number of drugs in development and
global burden of diseasemeasures.METHODS: Burden of disease data (DALYs, YLL,
YLD, and mortality) for the top 29 most prevalent conditions were obtained from
WHO 2004 Global Burden of Disease Project. Data on drugs in development were
obtained from Adis R&D Insights (Adis International Limited). Our a priori hypoth-
esis was no relationship between the number of drugs in development (2011) and
2004 GBD metrics. Predictor and outcomes variables were log-transformed to re-
duce positive skew; following univariate linear regression analysis all measure of
burden of disease or public interest whose p0.05 were included in a stepwise
multivariate regression model. RESULTS: Univariate linear regressions demon-
strated nomeasures of current GBD (DALYs, YLL, YLD, mortality; p 0.31, 0.66, 0.2,
0.15 respectively) correlated with the current drug development pipeline. Further,
we found no correlation between future DALY projections (2008, 2015, and 2030)
and global pipeline (p  0.2, 0.26, 0.33). CONCLUSIONS: Data suggest that global
R&Dpipeline is not optimally poised to reduce current or future burden. The lack of
correlation demonstrates the need for a better metric to guide healthcare resource
allocation. We propose a “public health index” that incorporates public health
variables such as the number of available interventions, economic impact, adher-
ence, education and prevention to prioritize disease areas for drug development
targeted to maximum public health impact.
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THE RELATIONSHIP BETWEEN PSEUDOEPHEDRINE SALES AND CLANDESTINE
METHAMPHETAMINE LABS
Talbert J, Blumenschein K, Freeman PR
University of Kentucky, Lexington, KY, USA
OBJECTIVES: The illicit production of methamphetamine from the precursor
chemical pseudoephedrine (PSE) in clandestine laboratories fuels a significant por-
tion of the domestic methamphetamine supply. Although states and the federal
government have taken steps to control access to PSE, it continues to be available
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as a non-prescription drug in all but two states. The purpose of this project was to
assess the relationship between PSE sales and indicators of methamphetamine
supply, specifically the number of clandestine laboratory incidents reported, in
Kentucky. METHODS: We calculate regression models predicting clandestine
methamphetamine lab incidents using 2010 county level Kentucky data. Explana-
tory factors include PSE sales (in grams), methamphetamine-related hospitaliza-
tions, USDA urban/rural indicator, methamphetamine related arrest, controlled
substance (CS) prescriptions dispensed, and population. Data sources include the
Kentucky All Schedule Prescription Electronic Reporting Program, the Kentucky
Inpatient Discharge Data Set, the Kentucky State Policy Crime in Kentucky Report,
and Clandestine Laboratory Surveillance System. RESULTS: Results indicate a
strong relationship between PSE sales and clandestine labs (p.001). Population
has a negative relationship to labs, with larger counties less likely to have clandes-
tine labs (P.002). Methamphetamine related hospitalizations have a positive re-
lationship to labs (P .001). Methamphetamine related arrests have a negative
relationship to labs (P .05).CONCLUSIONS: PSE sales have a strong relationship to
clandestine labs, with greater sales of PSE leading to a greater number of clandes-
tine labs. Our findings have important policy implications as states struggle with
policy options to reducemethamphetamine abuse. Tighter restrictions on PSEmay
be justified as a means to reduce clandestine methamphetamine labs.
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OBJECTIVES: The Drug Safety and Effectiveness Network (DSEN) in Canada was
created in response formore evidence on ‘real world’ drug safety and effectiveness
in the post-market phase. The goal of the Network Meta-Analysis (NMA) Collabor-
ative was to establish within DSEN an innovative partnership of health methodol-
ogists with four distinct yet complementary areas of expertise relevant to network
meta-analysis (biostatistics, safety/effectiveness systematic reviews, health eco-
nomics, and knowledge translation) and closely linked with international experts
and partner organizations such as ISPOR that are actively involved in health
research. METHODS: A proposal was developed and submitted to the Canadian
Institutes of Health Research (CIHR) for establishing a Collaborative for providing
rapid response to specific queries by utilizing network meta-analysis and safety
and effectiveness systematic reviews; providing a proactive platform for the devel-
opment and application of innovative, sophisticated, leading edge analyticalmeth-
ods for NMA and safety and effectiveness systematic reviews; developing knowl-
edge translation strategies that fill gaps in knowledge required by end-users to
make evidence-based decisions about drug safety and effectiveness that are based
on NMAs; establishing practical and interactive training and mentorship opportu-
nities for trainees through international links with partners specializing in drug
safety and effectiveness research. RESULTS: The proposal was peer-reviewed at
CIHR for responding to safety and effectiveness using NMA, developing innovative
NMA techniques, translating knowledge and building capacity. The proposal was
successful and funding was allocated. The demonstration project awarded was
evaluating neworal anti-coagulants compared towarfarin or lowmolecularweight
heparin in preventing stroke and other cardiovascular events in patientswith atrial
fibrillation. CONCLUSIONS: The infrastructure for the Collaborative will permit
safety and effectiveness reviews involving NMA to be conducted and innovative
methods developed. The first review completed on new oral anti-coagulants incor-
poratingNMAprovided informative comparisons between the anticoagulants from
both a therapeutic and economic perspective.
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OBJECTIVES: To test amore uniformly structured approach to evaluating evidence
for formulary decision making among managed care decision makers.METHODS:
A structured framework assessing the impact of costs, efficacy benefits, safety
concerns, and certainty of efficacy and safety evidence on formulary access was
tested using four hypothetical clinical conditions (breast cancer, osteoporosis, Alz-
heimer’s disease, and hypertension). After recruitment from a convenience sam-
ple, respondents were assigned via balanced incomplete block design to rate 12
scenarios per clinical condition on a 1-9 scale (1no access, 9 open access). Dis-
tribution of ratings, means, medians, and rate of disagreement was calculated.
Mixed effects linear regression models using maximum likelihood, with rater as a
random effect, were fit to estimate the association of clinical condition, cost, effi-
cacy certainty, safety certainty, efficacy benefit, and safety concerns with level of
formulary access. RESULTS: Seventy-nine P&T decision-makers completed the
survey between February-October 2011 resulting in 3783 evaluable responses
(2823pharmacy directors, 960medical directors). Mean ratings were lower
among pharmacy directors vs. medical directors (3.92 vs. 4.36, p0.093). Adjusted
formulary access ratings differed by clinical condition (breast cancer 4.40; osteo-
porosis 4.04; Alzheimer’s 4.00, and hypertension 3.70). Individual raters had sub-
stantial disagreement in individual scenario ratings (MAD 0.25-2.19). Across all
conditions, greater formulary access was significantly associated with greater cer-
tainty of safety evidence (high vs. low 1.60), greater certainty of efficacy evidence
(0.72), greater magnitude of efficacy benefit (0.43), fewer safety concerns (0.22) and
lower comparative cost (0.54). CONCLUSIONS: Greater formulary access was asso-
ciated with greater efficacy benefit, certainty of efficacy and safety evidence, lower
costs, and fewer safety concerns. Despite substantial inter-rater variation within
each scenario, the structure of the framework held during testing with a broad
number of P&T decision-makers, suggesting a more structured approach may re-
sult in greater clarity and transparency in formulary decision-making.
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OBJECTIVES: To evaluate medication adherence and persistence in patients with
acute coronary syndromes (ACS) who initiated prasugrel following a percutaneous
coronary intervention (PCI).METHODS:We identified adult patients with no prior
stroke/transient ischemic attack who filled prasugrel as their first dispensed out-
patient thienopyridine within 30 days post ACS-PCI discharge from July 10, 2009 to
June 30, 2010 using claims from the Thomson ReutersMarketscan dataset. Baseline
characteristics were assessed in the 6 months prior to the index hospitalization,
and patients were required to have 12 months of continuous enrollment post-
discharge. Predictors of adherence 80%, calculated using the medication posses-
sion ratio (MPR) during the 12-month follow-up period, were identified using a
logistic regression model. Persistence was assessed with survival analysis tech-
niques using a15-day gap to define a discontinuation. ACoxproportional hazards
model identified predictors of prasugrel discontinuation. RESULTS:The cohortwas
composed of 1340 patients with a mean age of 56.3 years; 79.5% were male. The
average MPR was 0.79 and nearly 70% of patients had adherence 80%. Patients
with prior statin use had higher odds of adherence (OR: 1.59, 95% CI: 1.22-2.09).
Coagulation defects (OR: 0.13, 95% CI: 0.03-0.52), baseline depression (OR: 0.33, 95%
CI: 0.14-0.75), history of bleeding (OR: 0.44, 95%CI: 0.20-0.95), prior PCI (OR: 0.61, 95%
CI: 0.39-0.94), and prior clopidogrel use (OR: 0.68, 95% CI: 0.46-1.00) were associated
with decreased odds of adherence. The median time to prasugrel discontinuation
was 242 days. Baseline factors associated with prasugrel discontinuation were
prior anemia (HR: 1.65, 95% CI: 1.21-2.25), prior cardiomyopathy (HR: 2.07, 95% CI:
1.02-4.19), and prior deep vein thrombosis (HR: 2.71, 95% CI: 1.00-7.32).
CONCLUSIONS: Adherence to prasugrel following ACS-PCI was relatively high. Pa-
tients with coagulation defects or depression at baseline had the highest odds of
suboptimal adherence. Anemia, prior DVT and cardiomyopathy were among fac-
tors associated with prasugrel early discontinuation.
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OBJECTIVES: Adherence comparisons of biologic agents used to treat Crohn’s dis-
ease (CD) have typically compared adherent and non-adherent patients. Non-ad-
herence may be due to efficacy, tolerability, lack of follow-up or patient-centered
reasons. There is a need for a more in-depth examination of non-adherence. Pur-
pose was to compare healthcare costs of CD patients who were adherent vs. inter-
mittently adherent on infliximab (IFX) therapy.METHODS: Patients with1 claims
for IFX initiated between 1/1/2006-12/31/2009 who had 2 diagnoses of CD (ICD-9-
CM: 555.XX) during the pre-index period were identified from Thomson Reuters
Marketscan®Databases. Patients had to be18 years, continuously enrolled for 12
months before and after IFX initiation, and had no prior use of IFX during 360-days
pre-index. Patients with prior biologic therapy or rheumatoid arthritis (ICD-9-CM:
714.XX) were excluded. Adherent group was classified as having amedication pos-
session ratio (MPR) of 80%; intermittently adherent group had an MPR80% with
IFX claims spanning 90% or more of the observation period. Differences between
the adherent and intermittently adherent groups were assessed using propensity-
weighted general linear models. RESULTS: A total of 599 CD patients were identi-
fied (360 adherent; 239 intermittently adherent) with a mean (SD) age of 42.9 (15.5)
and 50.9% were female. Propensity-weighted mean total healthcare costs exclud-
ing IFX were $13,097 vs. $20,068 (P0.0001) for the adherent vs. intermittently
adherent groups. Mean all-cause component costs were $2,764 vs. $6,665 (P0.001)
for hospitalizations, and $7,074 vs. $10,196 (P0.0001) for outpatient visits among
the adherent vs. intermittently adherent groups, respectively; no significant cost
differences were observed in ER visits, other prescription or total costs (component
 IFX). CONCLUSIONS:Adherencewas associatedwith lower total non-IFX health-
care costs. Comparison of adherent vs. intermittently adherent patients may pro-
vide a conservative test of the effect of adherence since patients that were inter-
mittently adherent have some IFX exposure.
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